Mabwell Initiates First Clinical Trial of Novel Cancer Treatment 7MW4911 in the U.S. Mabwell has commenced a clinical trial in the U.S. for its groundbreaking antibody-drug conjugate 7MW4911, aimed at treating advanced colorectal cancer.

Mabwell Initiates First Clinical Trial of Novel Cancer Treatment 7MW4911 in the U.S. #China #Shanghai #oncology #Mabwell #7MW4911

Mabwell's Adalimumab Biosimilar Achieves Marketing Approval in Indonesia Mabwell's Adalimumab Biosimilar, known as 9MW0113, gains marketing authorization in Indonesia, enhancing global healthcare access and opportunities.

Mabwell's Adalimumab Biosimilar Achieves Marketing Approval in Indonesia #Indonesia #Jakarta #Mabwell #Adalimumab #JUNMAIKANG

Mabwell Initiates Phase II Trial for Anti-IL-11 Antibody Targeting Pathological Scarring Mabwell marks a milestone with the first dosing in China of its innovative anti-IL-11 antibody, aiming to treat pathological scarring in a Phase II trial.

Mabwell Initiates Phase II Trial for Anti-IL-11 Antibody Targeting Pathological Scarring #China #Shanghai #Mabwell #Anti-IL-11 #Pathological_Scarring

Mabwell's Groundbreaking Anti-ST2 Monoclonal Antibody 9MW1911 Receives FDA IND Clearance for COPD Study Mabwell has obtained FDA IND clearance for its innovative anti-ST2 monoclonal antibody 9MW1911, set to enter Phase IIa clinical trials for COPD.

Mabwell's Groundbreaking Anti-ST2 Monoclonal Antibody 9MW1911 Receives FDA IND Clearance for COPD Study #China #Shanghai #Mabwell #9MW1911 #anti-ST2

Mabwell's Strategic Global Expansion with First Overseas Shipment of Denosumab Injection Mabwell has made a significant move by announcing the first overseas shipment of its Denosumab Injection, emphasizing its globalization strategy and market expansion.

Mabwell's Strategic Global Expansion with First Overseas Shipment of Denosumab Injection #China #Shanghai #pharmaceuticals #Denosumab #Mabwell

Mabwell Reports Significant Reduction in COPD Exacerbations with 9MW1911 Antibody in Phase IIa Study Mabwell has reported promising Phase IIa results showing over 40% reduction in severe COPD exacerbations with their anti-ST2 antibody 9MW1911. This breakthrough could revolutionize treatment.

Mabwell Reports Significant Reduction in COPD Exacerbations with 9MW1911 Antibody in Phase IIa Study #China #Shanghai #Mabwell #COPD #9MW1911

Mabwell Advances Cancer Treatment with First Patient Dosed in Clinical Trial for CDH17-Targeting ADC 7MW4911 Mabwell has initiated a Phase I/II clinical trial for its novel CDH17-targeting ADC 7MW4911, marking a significant step in cancer treatment.

Mabwell Advances Cancer Treatment with First Patient Dosed in Clinical Trial for CDH17-Targeting ADC 7MW4911 #China #Shanghai #ADC #Mabwell #7MW4911

Mabwell's Breakthrough Monoclonal Antibody 9MW3811 Approved for Clinical Trials Targeting Pathological Scarring Mabwell has received approval from NMPA to begin Phase II trials for its innovative anti-IL-11 monoclonal antibody, 9MW3811, targeting pathological scarring.

Mabwell's Breakthrough Monoclonal Antibody 9MW3811 Approved for Clinical Trials Targeting Pathological Scarring #China #Shanghai #Mabwell #monoclonal_antibody #9MW3811

Mabwell to Present Promising Clinical Results of B7-H3 ADC at ESMO 2025 Mabwell will showcase the encouraging findings of its B7-H3-targeting ADC, 7MW3711, for advanced tumors at the upcoming ESMO Congress.

Mabwell to Present Promising Clinical Results of B7-H3 ADC at ESMO 2025 #ADC #Mabwell #7MW3711

Mabwell's Innovative CDH17-targeting ADC 7MW4911 Gains Regulatory Approval for Clinical Trials Mabwell has received IND clearance for its CDH17-targeting ADC 7MW4911 from China's NMPA, aiming for clinical studies in advancing gastrointestinal cancers.

Mabwell's Innovative CDH17-targeting ADC 7MW4911 Gains Regulatory Approval for Clinical Trials #China #Shanghai #ADC #Mabwell #CDH17

Mabwell Achieves Landmark Approval for Denosumab Injection in Pakistan Mabwell, in collaboration with The Searle Company, has gained Pakistan's first approval for denosumab injections, enhancing local treatment options.

Mabwell Achieves Landmark Approval for Denosumab Injection in Pakistan #Pakistan #Karachi #Denosumab #Mabwell #Searle

Mabwell's Innovative CDH17-Targeting ADC Gains FDA IND Approval Mabwell has received IND clearance from the FDA for its innovative CDH17-targeting ADC 7MW4911, set to enter clinical trials for advanced gastrointestinal cancers.

Mabwell's Innovative CDH17-Targeting ADC Gains FDA IND Approval #Mabwell #CDH17 #7MW4911

Mabwell Achieves Milestone in TNBC Treatment with New Drug in US Trials Mabwell makes strides in cancer treatment with the first patient dosed in the US for its advanced therapy targeting TNBC. This landmark trial represents a significant step in addressing unmet medical needs.

Mabwell Achieves Milestone in TNBC Treatment with New Drug in US Trials #United_States #New_York #TNBC #Mabwell #Bulumtatug_Fuvedotin

Mabwell's CDH17-Targeting ADC 7MW4911 Gains IND Approval from NMPA and FDA Mabwell's innovative ADC, 7MW4911, targeting CDH17, has received IND application acceptance from both the NMPA and FDA, marking a significant step in cancer treatment.

Mabwell's CDH17-Targeting ADC 7MW4911 Gains IND Approval from NMPA and FDA #China #Shanghai #Mabwell #CDH17 #7MW4911

Mabwell Signs Exclusive License Agreement with Qilu Pharma for Albipagrastim alfa Injection Mabwell has entered into a significant agreement with Qilu Pharmaceutical for the development and commercialization of Albipagrastim alfa in Greater China. The deal is a major step in enhancing cancer treatment efficacy.

Mabwell Signs Exclusive License Agreement with Qilu Pharma for Albipagrastim alfa Injection #China #Shanghai #Mabwell #Albipagrastim #Qilu_Pharma

Mabwell Showcases Promising Results of 9MW2821 at the 2025 ASCO Annual Meeting At the ASCO 2025 Annual Meeting, Mabwell highlighted the efficacy of its 9MW2821 treatment for advanced urothelial carcinoma, showcasing significant response rates.

Mabwell Showcases Promising Results of 9MW2821 at the 2025 ASCO Annual Meeting #USA #Chicago #Mabwell #Nectin-4 #9MW2821

Mabwell Achieves Significant Milestone with NMPA Approval of Albipagrastim alfa Injection Mabwell receives NMPA approval for Albipagrastim alfa injection, enhancing treatment options for cancer patients facing neutropenia.

Mabwell Achieves Significant Milestone with NMPA Approval of Albipagrastim alfa Injection #China #Shanghai #Mabwell #Albipagrastim #MAILISHENG

Mabwell Unveils Promising ADCs Clinical Data for 2025 ASCO Annual Meeting Mabwell is set to showcase groundbreaking clinical research results at the ASCO Annual Meeting in 2025, with promising ADCs targeting various cancers.

Mabwell Unveils Promising ADCs Clinical Data for 2025 ASCO Annual Meeting #China #Shanghai #ADCs #Mabwell #CancerResearch

Mabwell Unveils Innovative Drug Study Results at 2025 AACR Annual Meeting Mabwell presented six groundbreaking drug study results at the 2025 AACR Annual Meeting, showcasing advancements in cancer therapies and biopharmaceuticals.

Mabwell Unveils Innovative Drug Study Results at 2025 AACR Annual Meeting #China #Shanghai #cancer_therapies #ADCs #Mabwell

Mabwell to Unveil Clinical Findings of 9MW2821 and Toripalimab for Urothelial Carcinoma at ASCO 2025 Mabwell will present groundbreaking clinical data for 9MW2821 combined with toripalimab in urothelial carcinoma patients at ASCO 2025, showcasing innovation in biopharmaceuticals.

Mabwell to Unveil Clinical Findings of 9MW2821 and Toripalimab for Urothelial Carcinoma at ASCO 2025 #USA #Chicago #Mabwell #Toripalimab #9MW2821

Mabwell to Showcase Six Innovative Studies at 2025 AACR Annual Meeting in Chicago Mabwell prepares to reveal findings from six critical studies at the 2025 AACR Annual Meeting, focusing on cancer therapies and innovations.

Mabwell to Showcase Six Innovative Studies at 2025 AACR Annual Meeting in Chicago #China #Shanghai #biopharmaceuticals #Mabwell #AACR

Mabwell Achieves Breakthrough Designation for Nectin-4 ADC Therapy with High Response Rates Mabwell announces a groundbreaking achievement with its Nectin-4 targeted ADC therapy, showing impressive response rates and receiving breakthrough designation.

Mabwell Achieves Breakthrough Designation for Nectin-4 ADC Therapy with High Response Rates #China #Shanghai #Mabwell #Nectin-4 #ADC_therapy